Drug Approval | December 20, 2021
Cipla receives final approval for Lanreotide injection
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
The product will be commercialized from Unichem's Ghaziabad plant
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
Subscribe To Our Newsletter & Stay Updated
